title: [Pharmacological treatment for diabetic macular edema].
abstract: Diabetic macular edema(DME) is a major cause of vision loss and has a remarkable impact on the quality of life of diabetic patients. New pharmacological approaches based on the use of intravitreal drugs, such as corticosteroids and anti-vascular endothelial growth factor, have recently been developed for the treatment of DME. Even though laser therapy has been the standard treatment for DME, the results of several clinical trials have shown the superiority of some of these new agents to laser therapy. The purpose of this review is to briefly summarize the currently available new pharmacological treatments for DME in Japan.
authors: Masanori
authors: M
authors: Fukumoto
authors: Tsunehiko
authors: T
authors: Ikeda
mesh_terms: D000305:Adrenal Cortex Hormones; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D000305:Adrenal Cortex Hormones; D042461:Vascular Endothelial Growth Factor A